- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
More ▼
Key statistics
On Friday, Charles River Laboratories International Inc (CRL:NYQ) closed at 221.61, -19.41% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 225.29 |
---|---|
High | 225.29 |
Low | 220.37 |
Bid | 208.21 |
Offer | 228.72 |
Previous close | 224.75 |
Average volume | 706.67k |
---|---|
Shares outstanding | 51.51m |
Free float | 50.58m |
P/E (TTM) | 26.80 |
Market cap | 11.77bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of May 18 2024 00:00 BST.
More ▼